Since insulin resistance plays a crucial role in the pathogenesis of NAFLD and NASH, GLP-1 and its analogs have been considered a promising therapy for these conditions. The gene discussed is GLP1R; the disease is metabolic dysfunction-associated steatotic liver disease.